Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Adamas Pharmaceuticals Inc. (ADMS)

5.61   -0.14 (-2.43%) 02-14 16:00
Open: 5.71 Pre. Close: 5.75
High: 5.7827 Low: 5.475
Volume: 331,049 Market Cap: 156M
Adamas Pharmaceuticals Inc is a pharmaceutical company focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The Company is developing its wholly-owned product candidate, ADS-5102.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.926 - 5.958 5.958 - 5.985
Low: 5.395 - 5.434 5.434 - 5.466
Close: 5.551 - 5.611 5.611 - 5.66

Technical analysis

as of: 2020-02-14 4:26:19 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 7.16     One year: 8.36
Support: Support1: 5.40    Support2: 4.95
Resistance: Resistance1: 6.13    Resistance2: 7.16
Pivot: 5.47
Moving Average: MA(5): 5.69     MA(20): 5.56
MA(100): 5.06     MA(250): 5.91
MACD: MACD(12,26): 0.14     Signal(9): 0.13
Stochastic oscillator: %K(14,3): 76.17     %D(3): 72.63
RSI: RSI(14): 53.72
52-week: High: 12.57  Low: 3.35  Change(%): -47.5
Average Vol(K): 3-Month: 63419  10-Days: 21194

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
ADMS has closed below upper band by 34.8%. Bollinger Bands are 64.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to ADMS's normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action
NEW YORK, Feb. 5, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. between August 8, 2017 and September 30, 2019, inclusive (the "Class Period"), of the important February 10, 2020 lead plaintiff…

ADMS INVESTOR DEADLINE IN 7 DAYS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Adamas Pharmaceuticals, Inc.
NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action filed on behalf of investors that purchased or acquired the securities of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) between August 8, 2017, and September 30, 2019, inclusive (the “Class Period”). The lawsuit filed in the United States District Court for the Northern District of

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Drug Manufacturers - Specialty Generic
Shares Out. (M) 27.86
Shares Float (M) 22.62
% Held by Insiders 3.10
% Held by Institutions 71.69
Shares Short (K) 1850
Shares Short P. Month (K)

Stock Financials

EPS -4.030
Book Value (p.s.) 0.710
PEG Ratio -0.03
Profit Margin -215.09
Operating Margin -182.50
Return on Assets (ttm) -26.9
Return on Equity (ttm) -165.5
Qtrly Rev. Growth 31.3
Gross Profit (p.s.) 1.199
Sales Per Share
EBITDA (p.s.) -3.333
Qtrly Earnings Growth
Operating Cash Flow (M) -86.07
Levered Free Cash Flow (M) -56.34

Stock Valuations

P/E -1.39
P/E Growth Ratio -0.02
P/BV 7.90
P/S 3.00
P/CF -1.82

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.